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Abstract 
Background: Autophagy is demonstrated to be involved in acute ischemic stroke(AIS), which, however, is confined 
to cells and/or animals levels. The aim of this study was to determine two autophagy biomarkers, Beclin1 and LC3B, 
in cerebrospinal fluid (CSF) and serum of patients with AIS, and to evaluate a possible correlation between levels of 
Beclin1 and LC3B and severity of neurological deficit and clinical outcome of stroke patients.
Methods: Levels of Beclin1 and LC3B were quantified by ELISA in CSF and serum collected from 37 AIS patients 
and 21 controls. The clinical severity at stroke onset was determined by the National Institute of Health Stroke Scale 
(NIHSS) and the neurological outcome was determined by the Modified Rankin Scale (mRs) and the improvement in 
NIHSS between stroke onset and 3 months later. Associations between autophagy biomarkers and infarct volume, 
NIHSS and mRs were assessed using Pearson analysis.
Results: The levels of Beclin1 and LC3B were increased both in CSF and serum of AIS patients relative to controls. In 
CSF, they were positively correlated with infarct volume and NIHSS scores, and negatively correlated with mRs scores, 
but no significant association was observed in serum. Moreover, AIS patients with higher levels of Beclin1 and LC3B in 
CSF had significantly higher improvement in NIHSS.
Conclusion: CSF and serum levels of autophagy biomarkers are altered in AIS patients. CSF levels of autophagy bio‑
markers are associated with infarct volume, clinical severity of and neurological outcome.
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Background
Acute ischemic stroke (AIS) is a major cause of death 
and disablement all over the world [1]. Despite its high 
prevalence and increasing burden, there are no effective 
neuroprotective agents in clinical use [2, 3]. The tissue 
plasminogen activator (tPA) is the only approved drug for 
AIS [4]. However, the intravenous thromnolysis is lim-
ited due to the strict therapeutic window and high risk 
of hemorrhagic complications [5]. Thus, exploration of 
effective therapeutic strategy becomes a major challenge 
[6]. AIS can initiate a series of biochemical reactions 
that directly or indirectly injury cellular structures [7, 8]. 
Many substances are released into the cerebrospinal fluid 
(CSF) and blood during brain damage.
Recent studies have revealed that autophagy may 
play an important role in ischemic stroke [9, 10]. Many 
investigations indicate that stroke induces activation of 
autophagy [11]. Autophagy is a critical cellular process 
responsible for the degradation and recycling of cel-
lular components via the lysosomal pathway [12, 13]. 
This process is important for healthy cells to efficiently 
remove and recycle cellular constituents and maintain 
metabolic homeostasis [14]. Despite its essential role in 
cellular physiology, alterations in the process also operate 
as a pathological mechanism in many diseases, including 
brain damage [15, 16]. LC3B is a ubiquitin-like protein 
encoded by the mammalian homologue of autophagy 
Open Access
*Correspondence:  meillly@126.com; 2353352460@qq.com 
†Honghong Li and Shuwei Qiu contributed equally to this work
1 Department of Neurology, Sun Yat‑Sen Memorial Hospital, Sun Yat‑Sen 
University, No. 107 West Yanjiang Road, Guangzhou 510120, China
Full list of author information is available at the end of the article
Page 2 of 8Li et al. J Transl Med  (2015) 13:359 
associated gene 8 (Atg8) and is a reliable marker of active 
autophagosomes due to its tight correlation with num-
bers of autophagosomes [17, 18]. The synthesis of LC3B 
is increased during the process of autophagy, making 
it a key readout of levels of autophagy in mammalian 
cells [19, 20]. Beclin1, the mammalian homolog of yeast 
Atg6 and mammalian Vps15 [21], is an another marker 
of autophagy for its essential role for autophagy activa-
tion [22–24]. Some reports show that autophagy causes 
energy depletion, DNA fragmentation and severe damage 
in intracellular components [25–27]. By contrast, some 
other studies report the protective role of autophagy in 
ischemic injury [28–31]. Moreover, in vivo evidence from 
patients involving autophagy is still lacking and thus the 
role of autophagy in patients with ischemic stroke need 
more investigation [32–34].
The present study was designed to investigate the role 
of autophagy in AIS patients, with Beclin1 and LC3B 
used as markers of autophagy. Our study showed that 
levels of Beclin1 and LC3B greatly increased both in 
CSF and serum of patients with AIS. More interestingly, 
we found that Beclin1 and LC3B in CSF were correlated 




This study was performed in Sun Yat-Sen Memorial Hos-
pital of Sun Yat-Sen University from Mar. 2013 through 
Dec. 2014. To accurately evaluate the effect of autophagy 
on acute ischemia injury, the patients who met the fol-
lowing criteria were included: (1) the first ever stroke, 
without history of cerebrovascular disease; (2) within 
24 h after onset; (3) age ≥18 years; (4) evidence of previ-
ous infarct lesion by brain computed tomography (CT) or 
magnetic resonance (MR); (5) willing to sign a informed 
consent document. The exclusion criteria were as follows: 
(1) concomitant systemic disease such as cardiovascular 
disease; (2) concomitant malignant disease; (3) history 
of diabetes; (4) history of surgery or trauma recently; 
(5) with autoimmune disease or treated with hormone 
or immuneinhibitors; (6) with neurological degenerative 
disease, such as Alzheimer’s disease, Parkinson’s disease, 
motor neuron disease, and multiple system atrophy; (7) 
receiving thrombolysis treatment. Forty-two AIS patients 
were included in the experimental group, and 5 patients 
were excluded due to the loss to follow-up when we 
assessed the mRS and NIHSS scores 3 months later after 
the stroke.
Detailed neurological examination and brain magnetic 
resonance imaging (MRI) 3.0T with diffusion weighted 
images (DWI) were performed in all AIS patients. Acute 
cerebral infarction was defined as an area of high signal 
intensity on the DWI. The edge of each infarct lesion 
was draw by the manual approach and the total infarct 
volume of each patient was calculated automatically by 
software Volume Viewer 2 (GE, AW Suite 2.0, 6.5.1.z) 
as previously described [35, 36]. To evaluate the sever-
ity of neurological deficit after AIS, a neurological deficit 
grading system National Institute of Health Stroke Scale 
(NIHSS) [37] was performed on each AIS patient within 
24  h of stroke onset. The evaluation was performed 
immediately after blood and CSF samples were obtained 
and 3 months later it was repeated. The clinical outcome 
of AIS was determined by the Modified Rankins Scale 
(mRS) assessed 3  months after stroke and the improve-
ment in NIHSS (ΔNIHSS) as previously described 
[38]. The ΔNIHSS was defined as the improvement in 
NIHSS = NIHSS24h − NIHSS3 months [38]. The MRI stud-
ies, NIHSS and mRS were evaluated by two neurologists 
who were blinded to the study.
The control subjects were selected from 21 age- and 
gender-matched patients with no central nervous sys-
tem (CNS) disease, including psychoneurosis (n  =  15), 
benign paroxysmal positional vertigo (n = 3), trigeminal 
neuralgia (n = 1), hypokalemic periodic paralysis (n = 1) 
and progressive muscular dystrophy (n = 1).
This study was approved by the Ethical Committee of 
the Sun Yat-Sen Memorial Hospital, Sun Yat-Sen Uni-
versity and conducted in accordance with the principles 
of the Declaration of Helsinki. All the participants were 
informed about the study and agreed to participate by 
signing an informed consent form.
CSF and serum sample collection
CSF and peripheral blood samples of patients with AIS 
were collected within 10–24 h of the onset of neurologi-
cal symptoms. CSF samples were taken during lumbar 
puncture between the L3/4 or L4/5 intervertebral space 
using a 25-gauge needle and held immediately on ice. 
Peripheral blood samples were collected by venepuncture 
in heparinized tubes and stored on ice. The CSF samples 
were centrifuged at 800 rpm for 5 min at +4 °C, and the 
blood samples were centrifuged at 3000 rpm for 15 min 
at +4  °C. All samples were stored at −80  °C until they 
were analyzed.
Analysis of CSF and serum
Concentrations of two autophagy biomarkers, Beclin1 
and LC3B, in CSF and blood were measured by com-
mercial enzyme-linked immuno sorbent assay (ELISA) 
kits following the manufacturer’s instructions (SunLong 
Biotech Co., LTD, China). Briefly, for Beclin1 and LC3B 
evaluation CSF and serum samples were diluted 5 times. 
The optical density (OD) was measured by Microplate 
reader (Teng instrument co., LTD, USA) at a wavelength 
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of 450  nm. A standard curve linear regression equation 
was calculated according to standards’ concentrations. 
Then, the concentrations of Beclin1 and LC3B in CSF 
and serum were calculated by the regression equation.
Statistical analysis
All statistical analyses were performed by SPSS Statis-
tics, version 19.0 software (SPSS, Inc, Armonk, NY). All 
graphs were generated by GraphPad Prism version 5.00 
(GraphPad Software, San Diego,CA USA). All data were 
expressed as mean  ±  standard deviation (SD). Differ-
ences in characteristics between the AIS patients and 
controls were evaluated using the Student’s t-test for 
continuous variables or Chi square test for dischotomous 
variables. The Mann–Whitney U Test was used to com-
pare the autophagy biomarkers between the AIS patients 
and controls. Differences in good outcome group and 
poor outcome group assessed by the improvement in 
NIHSS were evualted by the Student’s t-test. Pearson’s 
correlation test was used to assess the linear depend-
ence between autophagy biomarkers and infarct volume, 




Patients were enrolled between Mar. 2013 and Dec. 2014. 
From the 42 AIS patients who were primarily included, 
5 patients were excluded due to the loss to follow-up. 
Thus the final analysis was conducted on 37 AIS patients 
and 21 control subjects. Their demographic clinical 
characteristics are presented in Table  1. There were no 
significant differences in age, gender, blood pressure, 
cholesterol, low-density lipoprotein cholesterol (LDL-C), 
high-density lipoprotein cholesterol (HDL-C), triglycer-
ide, and serum glucose between patients with AIS and 
controls.
Beclin1 and LC3B concentrations
In the observed population, samples were collected 
within 10–24  h of stroke onset. Firstly, we analyzed the 
change of levels of Beclin1 and LC3B both in CSF and 
serum of AIS patients. Concentrations of Beclin1 and 
LC3B in CSF and serum of AIS patients were significantly 
higher than that of control subjects (Fig. 1).
Association between Beclin1 and LC3B and infarct volume 
and NIHSS
We also investigated the association between autophagy 
and infarct volume and clinical severity of neurologi-
cal deficit assessed by NIHSS in AIS patients. The mean 
infarct volume for all AIS patients was 8.82 ± 6.63 cm3. 
The mean NIHSS score for all AIS patients was 
6.41 ± 3.578. In CSF, concentrations of Beclin1 and LC3B 
were positively correlated with infarct volume (Fig.  2a, 
c) and NIHSS (Fig. 3a, c). In serum, no significant asso-
ciation was observed between Beclin1 and LC3B levels 
and infarct volume (Fig. 2b, d), as well as the serum Bec-
lin1 level and NIHSS (Fig.  3b). Although concentration 
of LC3B in serum was positively correlated with NIHSS 
(Fig. 3d), the correlation coefficient (r = 0.348) is low.
Association between Beclin1 and LC3B and clinical 
outcome
Then, all the AIS cases were followed up for 3  months 
to investigate the role of autophagy in the outcome of 
AIS. The primary outcome was evaluated by mRS. In 
CSF, levels of Beclin1 and LC3B were negatively corre-
lated with mRS (Fig. 4a, c), but no significant association 
was observed in serum (Fig.  4b, d). The improvement 
in NIHSS (ΔNIHSS  =  NIHSS24  h  −  NIHSS3 months) was 
selected as the second outcome measures. ΔNIHSS  ≥3 
was considered to be good outcome and ΔNIHSS <3 was 
considered to be poor outcome. As a result, 19 cases of 
AIS patients gained good outcome and 18 cases gained 
poor outcome. We found that levels of Beclin1 and 
LC3B in CSF were significantly higher in good outcome 
patients than in poor outcome patients (Fig. 5a, c). How-
ever, there was no significant difference between levels of 
Beclin1 and LC3B in serum and improvement in NIHSS 
(Fig. 5b, d). 
Discussion
It was well demonstrated that autophagy participates in 
ischemic stroke [39–41], while the present study firstly 
reported the involvement of autophagy in patients with 
Table 1 Demographics in  AIS patients and  controls 
(mean ± SD)
AIS acute ischemic stroke, Con control, SBP systolic pressure, DBP diastolic 
pressure, Chol cholesterol, LDL-C low-density lipoprotein cholesterol, HDL-C 
high-density lipoprotein cholesterol, TG triglyceride, GLU glucose
Variables AIS (n = 37) Con (n = 21) p value
Gender
 Male 17 10 0.559
 Female 20 11
Age 59.38 ± 14.88 51.90 ± 15.80 0.078
SBP (mmHg) 130.19 ± 21.77 126.76 ± 20.46 0.558
DBP (mmHg) 81.27 ± 11.55 79.76 ± 9.98 0.618
Chol (mmol/l) 5.12 ± 1.31 5.22 ± 1.19 0.777
LDL (mmol/l) 3.13 ± 0.86 3.23 ± 0.75 0.652
HDL (mmol/l) 1.10 ± 0.30 1.14 ± 0.30 0.682
TG (mmol/l) 1.88 ± 1.54 1.92 ± 1.48 0.92
GLU (mmol/l) 4.93 ± 0.98 4.88 ± 0.73 0.852
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AIS. This study found that Beclin1 and LC3B were obvi-
ously increased in both CSF and serum of patients with 
AIS, and that levels of Beclin1 and LC3B in CSF were 
positively correlated with infarct volume and severity 
of neurological deficit. Moreover, levels of Beclin1 and 
LC3B in CSF were associated with good outcome of AIS 
patients.
In CNS, autophagy can be activated by cerebral 
ischemia/hypoxia, nutrient deprivation, oxidative stress, 
energy crisis and neurotoxins [42–44]. The initial role 
of autophagy activation is to provide proper cellular 
response for nutrients limitation [45, 46]. Autophagy 
is activated for lack of essential nutrients after ischemia 
[47]. Transition from basal level into induced autophagy 
could be regulated by multiple pathways in neurons dur-
ing cerebral ischemic stroke [48]. Autophagy is activated 
not only by PI3  K-Akt-mTORC1 pathway [49], but also 
by AMP-activated protein kinase (AMPK) via activation 
Fig. 1 Levels of Beclin1 and LC3B in CSF (a) and serum (b) of controls (Con) and AIS. Concentrations of Beclin1 and LC3B both in CSF and serum 
were determined by ELISA (*p < 0.001)
Fig. 2 Associations between autophagy biomarkers and infarct volume (IV) in patients with AIS. The figures show a association between CSF 
Beclin1 and IV (r = 0.819, p < 0.001), b association between serum Beclin1 and IV (r = 0.268, p = 0.109), c association between CSF LC3B and IV 
(r = 0.821, p < 0.001), and d association between serum LC3B and IV (r = 0.324, p = 0.05)
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of ULK1 or by inhibition of mammalian target of rapa-
mycin complex (mTORC) [50]. Furthermore, increased 
AMP/ATP ratio and/or [Ca2+] activates AMPK kinase 
through activation of Ca2+/calmodulin-dependent pro-
tein kinase kinase (CaMKK) and LKB1 kinases, therefore 
inducing autophagy [51]. However, autophagy can be 
inhibited by the binding of Bcl-2 to Beclin1 via disrupting 
the association of Beclin1 with PI3K, hVps34 and p150 
[52]. Consistent with observations, our study showed 
that autophagy was activated in serum and CSF of AIS 
patients with indicators increased, suggesting critical 
roles of autophagy in ischemic process.
In this study, levels of Beclin1 and LC3B in CSF were 
positively correlated with infarct volume and sever-
ity of neurological deficit, whereas this relation was not 
observed in serum. This is likely to be due to: First, the 
autophagy biomarkers in serum can not accurately reflect 
their levels in brain, and they may be affected by other 
organs of bodies when stroke takes place. Second, the 
sample size in this study was small.
More importantly, increased concentrations of Beclin1 
and LC3B in CSF were found to be associated with good 
outcome, suggesting autophagy plays a protective role 
in AIS. Accumulating evidence suggests that autophagy 
enhanced functional recovery after stroke. It was repeat-
edly demonstrated that autophagy played a neuropro-
tective role in ischemic stroke. Urbanek et  al. reported 
that rapamycin can effectively prevent neuro damage 
by induction of protective autophagy [53]. Autophagy 
inhibitor 3-MA can alleviate the neurological symptoms 
after ischemic stroke [16]. Also, Gao et al. demonstrated 
that ER stress-induced autophagy contributes to neuro-
protective effect in cerebral ischemic preconditioning 
[54]. The protective role of autophagy in AIS was possibly 
attributed to elimination of damaged mitochondria and 
block of downstream apoptosis [41, 55]. However, it was 
also showed that autophagy could contribute to worse 
outcome [56, 57], and excessive activation of autophagy 
leads to neuronal death in ischemic stroke [58, 59]. In 
the neuronal system, moderate autophagy is thought 
to be neuroprotective [60], while excess or inadequate 
autophagy may promote neuronal cell death [61, 62]. In 
our study, the severity of neurologic deficit of most sub-
jects was mild to moderate, so the moderate activation of 
autophagy exacted neuroprotective role in AIS patients.
There were some limitations in the present study. First, 
it is difficult to determine concentrations of Beclin1 and 
LC3B in CSF from normal persons as controls. Second, 
Fig. 3 Associations between autophagy biomarkers and NIHSS scores in patients with AIS. a, c Correlation analysis between CSF Beclin1 and LC3B 
levels and NIHSS scores (Beclin1: r = 0.829, p < 0.001; LC3B: r = 0.819, p < 0.001). b, d Correlation analysis between serum Beclin1 and LC3B levels 
and NIHSS scores (Beclin1: r = 0.233, p = 0.165; LC3B: r = 0.348, p = 0.035)
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because of ethical concerns, our study was restricted to 
CSF and serum within 10–24 h of AIS, lacking of kinetic 
observation of alternations of Beclin1 and LC3B. Despite 
the limitations of the present study, our findings provide 
new evidence that autophagy was involved in AIS and 
was associated with clinical outcome.
In summary, we observed that autophagy biomarkers 
in CSF and serum levels of AIS patients were increased 
and that levels of Beclin1 and LC3B in the CSF were 
associated with good clinical outcome, implicating a 
thorough involvement of autophagy in ischemic injury 
and suggesting a bright intervention target in AIS 
treatment.
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